Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting
Retrieved on:
Monday, May 17, 2021
Biotechnology, Pharmaceutical, Health, Amyloidosis, Branches of biology, Proteins, Organ systems, Familial amyloid polyneuropathy, Transthyretin, Amyloid, Proteopathy, AA amyloidosis, AT-01 Pan-Amyloid Diagnostic, AT-02 PAR Therapeutic, AT-03 PAR Therapeutic, AT-04 PAR Therapeutic, Systemic Amyloidosis, Attralus, AT-01 PAN-AMYLOID DIAGNOSTIC, AT-02 PAR THERAPEUTIC, AT-03 PAR THERAPEUTIC, AT-04 PAR THERAPEUTIC, SYSTEMIC AMYLOIDOSIS, ATTRALUS
AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.
Key Points:
- AT-01 is a novel diagnostic that provides the potential to change the treatment paradigm by enabling detection of all types of systemic amyloidosis at all stages of disease.\xe2\x80\x9d\nCurrently, there are no FDA-approved imaging agents as diagnostics for systemic amyloidosis.
- Systemic amyloidosis is significantly underdiagnosed due to low awareness, lack of specific symptoms, and no current disease-specific diagnostics.
- The two most common forms of systemic amyloidosis are immunoglobulin light-chain (AL) amyloidosis and transthyretin amyloidosis (ATTR).\nAttralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.
- By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.